FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283275191> ?p ?o ?g. }

• W4283275191 endingPage "671" @default.
• W4283275191 startingPage "664" @default.
• W4283275191 abstract "The aim of this study is to evaluate the long-term efficacy, safety, and impact on immunoglobulin G (IgG) levels of rituximab in patients with myasthenia gravis (MG). A retrospective, observational study of drug-refractory MG patients treated with rituximab was done. The MG Foundation of America postintervention status (MGFA-PIS) was used to evaluate clinical response. Serum IgG levels were determined at baseline and post-treatment. Hypogammaglobulinemia was defined as IgG<7g/L. Thirty patients were included, 12 with anti-MuSK and 18 with anti-AChR antibodies. Mean (SD) follow-up was 85.5 (48) months. All 12 MuSK+ patients but only six (33%) AChR+ patients achieved minimal manifestations or remission (p<0.01). Nine severe infections were observed in five patients (17%). One patient was diagnosed with progressive multifocal leukoencephalopathy. At baseline, two patients (2/24; 8%) had hypogammaglobulinemia. During follow-up, hypogammaglobulinemia was observed in 60% (3/5) of patients who developed an infection and in 33% (7/21) who did not. Two of these patients died of infection-related complications. This study supports the effectiveness of rituximab in patients with MG, especially those with anti-MuSK antibodies. Severe infections may appear after rituximab treatment and hypogammaglobulinemia might play a role on it. A standard protocol would be needed to closely monitor IgG levels in MG patients treated with rituximab." @default.
• W4283275191 created "2022-06-23" @default.
• W4283275191 creator A5001639816 @default.
• W4283275191 creator A5010308866 @default.
• W4283275191 creator A5012853983 @default.
• W4283275191 creator A5013496858 @default.
• W4283275191 creator A5027059402 @default.
• W4283275191 creator A5042882165 @default.
• W4283275191 creator A5048129993 @default.
• W4283275191 creator A5061762173 @default.
• W4283275191 creator A5063949088 @default.
• W4283275191 creator A5065694401 @default.
• W4283275191 creator A5083013298 @default.
• W4283275191 date "2022-08-01" @default.
• W4283275191 modified "2023-10-16" @default.
• W4283275191 title "Rituximab in myasthenia gravis: efficacy, associated infections and risk of induced hypogammaglobulinemia" @default.
• W4283275191 cites W1967360492 @default.
• W4283275191 cites W1969295021 @default.
• W4283275191 cites W2000034375 @default.
• W4283275191 cites W2001791763 @default.
• W4283275191 cites W2013176883 @default.
• W4283275191 cites W2017506460 @default.
• W4283275191 cites W2021398160 @default.
• W4283275191 cites W2042412741 @default.
• W4283275191 cites W2064731149 @default.
• W4283275191 cites W2070412267 @default.
• W4283275191 cites W2082722055 @default.
• W4283275191 cites W2086332067 @default.
• W4283275191 cites W2104413012 @default.
• W4283275191 cites W2111680674 @default.
• W4283275191 cites W2134547577 @default.
• W4283275191 cites W2163100333 @default.
• W4283275191 cites W2176269625 @default.
• W4283275191 cites W2192934769 @default.
• W4283275191 cites W2269145518 @default.
• W4283275191 cites W2461303519 @default.
• W4283275191 cites W2507690749 @default.
• W4283275191 cites W2536452417 @default.
• W4283275191 cites W2555422834 @default.
• W4283275191 cites W2560852951 @default.
• W4283275191 cites W2586254189 @default.
• W4283275191 cites W2742758273 @default.
• W4283275191 cites W2791329038 @default.
• W4283275191 cites W2794906649 @default.
• W4283275191 cites W2800388833 @default.
• W4283275191 cites W2801527958 @default.
• W4283275191 cites W2900348232 @default.
• W4283275191 cites W2909823939 @default.
• W4283275191 cites W3023124841 @default.
• W4283275191 cites W3034624651 @default.
• W4283275191 cites W3043347176 @default.
• W4283275191 cites W4211188347 @default.
• W4283275191 doi "https://doi.org/10.1016/j.nmd.2022.06.006" @default.
• W4283275191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35811274" @default.
• W4283275191 hasPublicationYear "2022" @default.
• W4283275191 type Work @default.
• W4283275191 citedByCount "8" @default.
• W4283275191 countsByYear W42832751912022 @default.
• W4283275191 countsByYear W42832751912023 @default.
• W4283275191 crossrefType "journal-article" @default.
• W4283275191 hasAuthorship W4283275191A5001639816 @default.
• W4283275191 hasAuthorship W4283275191A5010308866 @default.
• W4283275191 hasAuthorship W4283275191A5012853983 @default.
• W4283275191 hasAuthorship W4283275191A5013496858 @default.
• W4283275191 hasAuthorship W4283275191A5027059402 @default.
• W4283275191 hasAuthorship W4283275191A5042882165 @default.
• W4283275191 hasAuthorship W4283275191A5048129993 @default.
• W4283275191 hasAuthorship W4283275191A5061762173 @default.
• W4283275191 hasAuthorship W4283275191A5063949088 @default.
• W4283275191 hasAuthorship W4283275191A5065694401 @default.
• W4283275191 hasAuthorship W4283275191A5083013298 @default.
• W4283275191 hasConcept C121332964 @default.
• W4283275191 hasConcept C126322002 @default.
• W4283275191 hasConcept C142424586 @default.
• W4283275191 hasConcept C159654299 @default.
• W4283275191 hasConcept C167135981 @default.
• W4283275191 hasConcept C187212893 @default.
• W4283275191 hasConcept C203014093 @default.
• W4283275191 hasConcept C2777805810 @default.
• W4283275191 hasConcept C2778105408 @default.
• W4283275191 hasConcept C2780653079 @default.
• W4283275191 hasConcept C71924100 @default.
• W4283275191 hasConcept C87355193 @default.
• W4283275191 hasConcept C90924648 @default.
• W4283275191 hasConceptScore W4283275191C121332964 @default.
• W4283275191 hasConceptScore W4283275191C126322002 @default.
• W4283275191 hasConceptScore W4283275191C142424586 @default.
• W4283275191 hasConceptScore W4283275191C159654299 @default.
• W4283275191 hasConceptScore W4283275191C167135981 @default.
• W4283275191 hasConceptScore W4283275191C187212893 @default.
• W4283275191 hasConceptScore W4283275191C203014093 @default.
• W4283275191 hasConceptScore W4283275191C2777805810 @default.
• W4283275191 hasConceptScore W4283275191C2778105408 @default.
• W4283275191 hasConceptScore W4283275191C2780653079 @default.
• W4283275191 hasConceptScore W4283275191C71924100 @default.
• W4283275191 hasConceptScore W4283275191C87355193 @default.
• W4283275191 hasConceptScore W4283275191C90924648 @default.
• W4283275191 hasIssue "8" @default.

• next